Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors.
OBJECTIVE
To determine the risk and the clinical predictors of in-hospital upper gastrointestinal (UGI) bleeding in patients with acute coronary syndromes (ACS), and to study the prophylactic role of proton pump inhibitors (PPI) in this setting.


BACKGROUND
Patients with ACS are usually treated by a combination of antiplatelet, antithrombotic and thrombolytic medications, thereby increasing the risk of bleeding.


METHODS
A retrospective study of 1023 patients hospitalized with ACS at the American University of Beirut Medical Center from September 2001 to November 2005. The main outcome measurements were the incidence of in-hospital UGI bleeding and its predictors; the utilization rate of PPI and its determinants.


RESULTS
Seven patients developed in-hospital UGI bleeding (0.7%) and 2 had major bleeding (0.2%). All required blood transfusion and none died in the hospital. Significant predictors of UGI bleeding were prior history of UGI bleeding or peptic ulcer disease (P<0.01), creatinine > 2 mg/dL (P=0.01), and home intake of aspirin, clopidogrel (P<0.05), or nonsteroidal anti-inflammatory drugs (P<0.05). Sixty-nine percent of patients received PPI during their hospital stay. There was no significant difference in the incidence of UGI bleeding between patients receiving and those not receiving PPI (0.7% vs. 0.6%, P= 0.88).


CONCLUSIONS
The risk of UGI bleeding is relatively low in patients hospitalized with ACS and does not appear to be significantly reduced by the use of PPI. The utilization rate of PPI was relatively high. Better patient selection and risk stratification for the prophylactic use of PPI are warranted.
Barada
Kassem
K
Department of Internal Medicine, American University of Beirut, Lebanon.
Karrowni
Wassef
W
Abdallah
Mouhamad
M
Shamseddeen
Wael
W
Sharara
Ala I
AI
Dakik
Habib A
HA
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D054058:Acute Coronary Syndrome / Q000150:complications* / Q000188:drug therapy; D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007861:Lebanon / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D011379:Prognosis; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D064750:Rabeprazole; D012189:Retrospective Studies; D012307:Risk Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D005343:Fibrinolytic Agents; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole